Common femoral vein-to-artery diameter ratio to detect elevated LVEDP
Official title: Common Femoral Vein-to-Artery Diameter Ratio for Detection of Elevated Left Ventricular End-Diastolic Pressure: Diagnostic Accuracy Study
Run by Burapha University · NCT07866859 · Data updated 2026-11-12
Researchers test whether the ratio of the common femoral vein to artery diameters, measured by ultrasound, can flag elevated LV end-diastolic pressure in patients having coronary angiography.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 100 Years |
| Sex | All |
| Enrollment | 105 (estimated) |
| Sponsor | Burapha University Academic / other |
| Locations | 1 site (Chon Buri) |
| Status | Recruiting |
| Started | October 1, 2026 |
| Main results expected | December 31, 2026 |
| Study ends | December 31, 2026 |
| Registry record updated | October 14, 2026 |
| Trial ID | NCT07866859 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (18+) undergoing coronary angiography with left heart catheterization at Burapha University Hospital who can have ultrasound measurements of femoral vessels obtained.
✕Probably not a fit
Patients in whom accurate ultrasound measurement cannot be obtained or in whom LVEDP measurement is not interpretable may not benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This prospective cross-sectional study looks at whether ultrasound measurements of the common femoral vein and artery diameters, and their ratio, can identify elevated LVEDP (defined as >16 mmHg) in adults undergoing coronary angiography and left heart catheterization. LVEDP is used as the reference standard for volume overload. Diagnostic performance is evaluated with ROC analysis to determine sensitivity and specificity of the diameter ratio. The study was conducted at Burapha University Hospital in Thailand with adults aged 18 or older and excludes patients where ultrasound measurements or catheterization are not feasible. The findings could help noninvasively screen for elevated LVEDP in patients with acute or chronic coronary syndromes and heart failure.
Why it matters
Potential benefit: If successful, the femoral vein-to-artery diameter ratio could provide a quick, noninvasive indicator of elevated LVEDP to guide management.
How similar studies have gone: Prior work using venous-to-arterial diameter relationships for diagnostic purposes in cardiovascular settings has shown promise but this exact ratio for LVEDP escalation is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult patients (aged ≥18 years) * Adult patients were scheduled to undergo coronary angiography with left heart catheterization Exclusion Criteria: * Contraindications to cardiac catheterization * Inability to obtain accurate ultrasonographic measurements of the common femoral vein or common femoral artery diameters * Inability to advance a guidewire across the aortic valve into the left ventricle for measurement of LVEDP.
Where it's running
-
Burapha University Hospital
Chon Buri, Thailand Recruiting
Study contacts
- Study coordinator: Sukrisd Koowattanatianchai, Doctor
- Email: sukrisd.ko@go.buu.ac.th
- Phone: +66-86633007
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Intrahospital flu vaccine for adults with high cardiovascular risk when admitted for ACS or heart failure
This study tests whether offering a flu vaccine at the bedside during a hospital stay, along with counseling, increases vaccination rates for adults with acute coronary syndrome or heart failure who are at high cardiovascular risk.
-
AI-driven Medipixel fractional flow reserve to guide PCI
This test checks whether an AI-based, angiography-derived Medipixel FFR method can guide PCI as safely and effectively as standard invasive pressure-wire FFR in adults with coronary artery disease.
-
Analyzing Blood Changes in Patients with Acute Coronary Syndrome
This study looks at blood samples from patients with acute coronary syndrome to see how their blood factors differ from those without heart disease, hoping to find clues about the condition's outlook.
-
Using Apple Watch data to predict heart failure outcomes
This study is testing if data from Apple Watches can help predict heart failure problems and the chances of needing to go back to the hospital for patients with heart failure.
-
Heart registry for patients after coronary interventions in South East Netherlands
This study is creating a registry to help doctors better understand and treat patients in South East Netherlands who have had heart procedures, aiming to reduce their risk of future heart problems.
-
Evaluating the impact of angiography-based FFR after heart procedures
This study is trying to see if measuring blood flow in heart arteries after a heart procedure can help predict serious heart problems and improve patients' quality of life.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.